Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MXBIO is a South Korean biotechnology company specializing in the development and manufacture of advanced biomaterials for bone and tissue regeneration. The company's product portfolio includes bovine-derived xenografts (MX-BONE), synthetic bone substitutes (MX-BONE S), and resorbable collagen membranes (MX-MEMBRANE), primarily targeting the dental and orthopedic markets. MXBIO also develops dental implant systems and is actively researching bio-active materials and drug delivery systems to enhance osteogenesis. With a strong focus on R&D, the company aims to provide innovative, biocompatible solutions that improve clinical outcomes in regenerative medicine. Its products are designed to facilitate rapid bone formation and tissue integration in complex clinical scenarios such as alveolar ridge augmentation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MXBIO.